Characteristics of HL cohort, SIR, and AER of mesothelioma after HL
| Characteristic . | No. (%) of patients . | Observed MM . | Expected MM . | SIR . | (95% CI) . | AER . | (95% CI) . |
|---|---|---|---|---|---|---|---|
| Overall | 2567 (100) | 13 | 0.51 | 25.7 | (13.7-44.0) | 3.5 | (1.8-6.1) |
| Sex | |||||||
| Male | 1437 (56) | 8 | 0.45 | 17.9 | (7.7-35.3) | 3.9 | (1.6-7.9) |
| Female | 1130 (44) | 5 | 0.06 | 85.2 | (27.6-199) | 3.0 | (0.9-7.1) |
| Age at first treatment of HL | |||||||
| Less than or equal to 30 y | 1559 (60.7) | 7 | 0.10 | 66.8 | (26.9-138) | 3.0 | (1.1-6.2) |
| 31-50 y | 1008 (39.3) | 6 | 0.40 | 15.0 | (5.5-32.5) | 4.4 | (1.4-9.8) |
| Treatment category* | |||||||
| Radiotherapy only | 730 (28.5) | 1 | 0.17 | 5.8 | (0.2-32.1) | 0.7 | (−0.1 to 4.7) |
| Chemotherapy only | 232 (9) | 0 | 0.06 | — | — | ||
| Radiotherapy + chemotherapy | 1605 (62.5) | 12 | 0.27 | 44.8 | (23.2-78.3) | 5.6 | (2.8-9.9) |
| Radiotherapy ± chemotherapy† | 2335 (91) | 13 | 0.44 | 29.5 | (15.7-50.4) | 3.9 | (2.0-6.7) |
| Follow-up | |||||||
| 5-25 y | 2287 (89.1) | 8 | 0.39 | 15.5 | (5.7-33.8) | 1.7 | (0.6-3.9) |
| More than or equal to 25 y | 280 (10.9) | 5 | 0.12 | 58.4 | (23.5-120) | 21.5 | (8.4-44.7) |
| Characteristic . | No. (%) of patients . | Observed MM . | Expected MM . | SIR . | (95% CI) . | AER . | (95% CI) . |
|---|---|---|---|---|---|---|---|
| Overall | 2567 (100) | 13 | 0.51 | 25.7 | (13.7-44.0) | 3.5 | (1.8-6.1) |
| Sex | |||||||
| Male | 1437 (56) | 8 | 0.45 | 17.9 | (7.7-35.3) | 3.9 | (1.6-7.9) |
| Female | 1130 (44) | 5 | 0.06 | 85.2 | (27.6-199) | 3.0 | (0.9-7.1) |
| Age at first treatment of HL | |||||||
| Less than or equal to 30 y | 1559 (60.7) | 7 | 0.10 | 66.8 | (26.9-138) | 3.0 | (1.1-6.2) |
| 31-50 y | 1008 (39.3) | 6 | 0.40 | 15.0 | (5.5-32.5) | 4.4 | (1.4-9.8) |
| Treatment category* | |||||||
| Radiotherapy only | 730 (28.5) | 1 | 0.17 | 5.8 | (0.2-32.1) | 0.7 | (−0.1 to 4.7) |
| Chemotherapy only | 232 (9) | 0 | 0.06 | — | — | ||
| Radiotherapy + chemotherapy | 1605 (62.5) | 12 | 0.27 | 44.8 | (23.2-78.3) | 5.6 | (2.8-9.9) |
| Radiotherapy ± chemotherapy† | 2335 (91) | 13 | 0.44 | 29.5 | (15.7-50.4) | 3.9 | (2.0-6.7) |
| Follow-up | |||||||
| 5-25 y | 2287 (89.1) | 8 | 0.39 | 15.5 | (5.7-33.8) | 1.7 | (0.6-3.9) |
| More than or equal to 25 y | 280 (10.9) | 5 | 0.12 | 58.4 | (23.5-120) | 21.5 | (8.4-44.7) |